Illumina, Inc. (NASDAQ:ILMN) announced the launch of Illumina SeqLab, an integrated solution for customers with HiSeq X™ Systems to enable large-scale human whole-genome sequencing operations. Designed to increase laboratory efficiency for population-scale, human whole-genome sequencing (HWGS), this new offering provides a complete solution for Illuminacustomers who need streamlined workflows with integrated sample tracking and fast and accurate analysis solutions. Illumina partnered with GenoLogics and Hamilton Robotics to provide this streamlined end-to-end solution which includes Clarity LIMS X Edition, Microlab® STAR™ liquid handling robotics, HiSeq® Analysis Software (HAS) v2.0 and Illumina SeqLab Consulting Service.
“This complete solution was important in our decision to purchase the HiSeq X System and to undertake population-scale whole-genome sequencing of large well-characterized cohorts in Scotland,” said Professor David Hume, Director of The Roslin Institute at the University of Edinburgh, which provided funding along with the Biotechnology and Biological Sciences Research Council for the HiSeq X System to be installed in the Institute.
Professor Tim Aitman, Director of Clinical Genomics in Edinburgh Genomics at the University of Edinburgh, added, “Having access to the best-in-class tools and quick access to service gives us confidence that we can ramp up quickly and spend more time studying the genomes of cancer patients, children with rare diseases, and people with disorders of the central nervous system, while spending less time on setting up our sequencing center.”
For laboratories that are new to population-level sequencing, developing and configuring the laboratory automation and software capabilities needed to process thousands of genomes per year can take significant resources and an extended period of time. The Illumina SeqLab plug-and-play solution helps laboratories maximize efficiency, optimize laboratory utilization and streamline analysis to enable maximum sample throughput in as little as six weeks. Moreover, it helps laboratories to deliver sequence results with confidence by enabling positive sample tracking throughout the laboratory process. As part of the service, expert consultants provide customers with detailed recommendations as they deploy Illumina’s suite of world-class technologies, leveraging the company’s more than 15 years of experience with genomics.
“The interest we’ve seen in population-scale sequencing as a result of the launch of the Illumina HiSeq X Ten Sequencing System last year and subsequent launch of the Illumina HiSeq X Five Sequencing System has far outpaced our expectations,” said Illumina Senior Vice President of Life Sciences, Kirk Malloy. “With this new solution, we are enabling more laboratories to undertake large-scale sequencing programs by providing them with premium solutions to scale rapidly and maximize efficiency.” (Original Source)
Shares of Illumina closed yesterday at $229.08. ILMN has a 1-year high of $232 and a 1-year low of $145.12. The stock’s 50-day moving average is $216.10 and its 200-day moving average is $198.79.
On the ratings front, Illumina has been the subject of a number of recent research reports. In a report issued on July 14, Wedbush analyst Zarak Khurshid maintained a Buy rating on ILMN, with a price target of $250, which implies an upside of 9.1% from current levels. Separately, on May 26, BTIG’s Dane Leone reiterated a Buy rating on the stock and has a price target of $240.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Zarak Khurshid and Dane Leone have a total average return of 6.7% and 13.5% respectively. Khurshid has a success rate of 66.0% and is ranked #1007 out of 3707 analysts, while Leone has a success rate of 81.6% and is ranked #523.
Illumina Inc providessequencing-and array-based solutions for genetic analysis. Itsproducts enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response.